SOLV
Solventum Corporation NYSE$67.44
Mkt Cap $11.7B
52w Low $62.38
19.6% of range
52w High $88.20
50d MA $68.04
200d MA $73.86
P/E (TTM)
7.5x
EV/EBITDA
7.0x
P/B
2.3x
Debt/Equity
1.0x
ROE
30.8%
P/FCF
-1379.6x
RSI (14)
—
ATR (14)
—
Beta
0.77
50d MA
$68.04
200d MA
$73.86
Avg Volume
1.3M
About
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site managemen…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | 1.50 | 1.57 | +4.7% | 76.94 | -5.1% | -3.6% | -5.1% | -8.0% | -8.5% | -8.0% | — |
| Nov 6, 2025 | AMC | 1.43 | 1.50 | +4.9% | 66.28 | +3.5% | +7.9% | +8.3% | +11.5% | +11.4% | +13.5% | — |
| Aug 7, 2025 | AMC | 1.45 | 1.69 | +16.6% | 71.95 | +3.4% | +2.0% | -0.1% | +0.2% | +3.4% | +1.7% | — |
| May 8, 2025 | AMC | 1.21 | 1.34 | +10.7% | 66.63 | +2.0% | +5.4% | +12.3% | +10.3% | +6.8% | +9.5% | — |
| Feb 27, 2025 | AMC | 1.31 | 1.41 | +7.6% | 83.44 | -3.0% | -4.4% | -3.9% | -5.3% | -6.7% | -9.2% | — |
| Nov 7, 2024 | AMC | 1.39 | 1.64 | +18.0% | 75.07 | +2.0% | -3.5% | -4.7% | -5.8% | -6.7% | -9.6% | — |
| Aug 8, 2024 | AMC | 1.51 | 1.56 | +3.3% | 58.66 | +2.3% | +3.3% | -1.6% | -0.8% | -1.5% | +0.3% | — |
| May 9, 2024 | AMC | 1.75 | 2.08 | +18.9% | 64.83 | -1.6% | -1.7% | -2.6% | +0.4% | -3.7% | -5.0% | — |
| Dec 31, 2023 | AMC | — | 0.42 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | 1.65 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $68.52 | $68.32 | -0.3% | +1.8% | -1.5% | -3.0% | -1.7% | -2.8% |
| Apr 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $68.88 | $70.00 | +1.6% | +2.3% | +1.7% | +0.1% | +0.3% | +0.1% |
| Feb 27 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $76.94 | $73.00 | -5.1% | -3.6% | -5.1% | -8.0% | -8.5% | -8.0% |
| Feb 27 | BTIG | Maintains | Buy → Buy | — | $76.94 | $73.00 | -5.1% | -3.6% | -5.1% | -8.0% | -8.5% | -8.0% |
| Feb 27 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $76.94 | $73.00 | -5.1% | -3.6% | -5.1% | -8.0% | -8.5% | -8.0% |
| Jan 26 | KeyBanc Capital Markets | Upgrade | Sector Weight → Overweight | — | $78.91 | $80.13 | +1.5% | +0.1% | -1.6% | -2.9% | -3.0% | -2.5% |
| Jan 20 | Mizuho | Upgrade | Neutral → Outperform | — | $79.48 | $79.56 | +0.1% | -0.7% | +1.1% | +1.0% | -0.7% | -0.6% |
| Jan 7 | Stifel | Maintains | Buy → Buy | — | $83.16 | $83.75 | +0.7% | +1.3% | +3.1% | +3.6% | +3.0% | -3.8% |
| Dec 2 | BTIG | Upgrade | Neutral → Buy | — | $85.56 | $87.30 | +2.0% | +0.0% | -0.4% | -0.4% | -0.2% | -3.5% |
| Nov 10 | UBS | Maintains | Neutral → Neutral | — | $71.52 | $71.25 | -0.4% | +0.4% | +3.3% | +3.2% | +5.2% | +5.8% |
Recent Filings
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
SOLV's departure of a key executive signals potential leadership instability and operational uncertainty, which could pressure the stock until management clarity emerges.
Mar 24
8-K
Solventum Corporation -- 8-K Filing
Solventum exceeded 2025 full-year sales and EPS expectations with strong fourth-quarter performance, delivering $0.36 GAAP and $1.57 adjusted diluted EPS, signaling operational momentum and execution on transformation initiatives.
Feb 26
Data updated apr 27, 2026 2:24am
· Source: massive.com